Skip to main content
SpringerLink
Log in

Calcium Antagonists in Cerebral/Peripheral Vascular Disorders

Current Status

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Ad Hoc Committee on Classification of Headache. Classification of headache. Journal of the American Medical Association 179: 717–718, 1962

    Article  Google Scholar 

  • Addonizio VP, Fisher CA, Ecmunds LH. Effects of verapamil and nifedipine on platelet activation. Clinical Research 28: 607A, 1980

    Google Scholar 

  • Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, et al. Cerebral arterial spasm — a controlled trial of nimodipine in patients with subarachnoid hemorrhage. New England Journal of Medicine 308: 619–624, 1983

    Article  PubMed  CAS  Google Scholar 

  • Antman EM, Stone PH, Muller JE, Braunwald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Annals of Internal Medicine 93: 875–885, 1980

    PubMed  CAS  Google Scholar 

  • Barnathan ES, Addonizio VP, Shattil SJ. Interaction of verapamil with human platelet α-adrenergic receptors. American Journal of Physiology 242: H19–H23, 1982

    PubMed  CAS  Google Scholar 

  • Blunt RJ, Porter JM. Raynaud’s syndrome. Seminars in Arthritis and Rheumatism 10: 282–308, 1981

    Article  PubMed  CAS  Google Scholar 

  • Bousser MG, Baron JC, Iba-Zizen MT, Comar D, et al. Migrainous cerebral infarction: a tomographic study of cerebral blood flow and oxygen extraction with the oxygen15 inhalation technique. Stroke 11: 145–148, 1980

    Article  PubMed  CAS  Google Scholar 

  • Braunwald E. Mechanism of action of calcium-channel blocking agents. New England Journal of Medicine 307: 1618–1627, 1982

    Article  PubMed  CAS  Google Scholar 

  • Coffman JD. Vasodilator drugs in peripheral vascular disease. New England Journal of Medicine 300: 713–717, 1979

    Article  PubMed  CAS  Google Scholar 

  • Coffman JD, Davies WT. Vasospastic diseases: a review. Progress in Cardiovascular Diseases 18: 123–146, 1975

    Article  PubMed  CAS  Google Scholar 

  • Conti CR, Pepine CJ, Feldman RL, Hill JA. Calcium antagonists. Cardiology 72: 297–321, 1985

    Article  PubMed  CAS  Google Scholar 

  • Dale J, Landmark KH, Myhre E. The effects of nifedipine, a calcium antagonist, on platelet function. American Heart Journal 105: 103–105, 1983

    Article  PubMed  CAS  Google Scholar 

  • Ellrodt AG, Singh BN. Clinical applications of slow channel blocking compounds. Pharmacology and Therapeutics 23: 1–43, 1983

    Article  PubMed  CAS  Google Scholar 

  • Fisher CM, Roberson GH, Ojemann RG. Cerebral vasospasm with ruptured sacular aneurysm — the clinical manifestations. Neurosurgery 1: 245–248, 1977

    Article  PubMed  CAS  Google Scholar 

  • Gelmers HJ. Effect of nimodipine (Bay e 9736) on postischemic cerebrovascular reactivity, as revealed by measuring regional cerebral blood flow (rCBF). Acta Neurochirurgica 63: 283–289, 1982

    Article  PubMed  CAS  Google Scholar 

  • Gelmers HJ. Nimodipine, a new calcium antagonist in the prophylactic treatment of migraine. Headache 23: 106–109, 1983

    Article  PubMed  CAS  Google Scholar 

  • Gelmers HJ. The effects of nimodipine on the clinical course of patients with acute ischemic stroke. Acta Neurologica Scandinavica 69: 232–239, 1984

    Article  PubMed  CAS  Google Scholar 

  • Gjørup T, Kelback H, Hartling OJ, Nielsen SL. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud’s phenomenon. American Heart Journal 111: 742–745, 1986

    Article  PubMed  Google Scholar 

  • Halperin JL, Coffman JD. Pathophysiology of Raynaud’s disease. Archives of Internal Medicine 139: 89–92, 1979

    Article  PubMed  CAS  Google Scholar 

  • Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia 5: 39–43, 1985

    Article  PubMed  CAS  Google Scholar 

  • Havanka-Kanniainen H, Myllyla VV, Hokkanen E. Nimodipine in the prophylaxis of migraine, a double-blind study. Acta Neurologica Scandinavica 90 (Suppl.): 77–78, 1982

    Google Scholar 

  • Johnsson H. Effects of nifedipine (Adalat) on platelet function in vitro and in vivo. Thrombosis Research 21: 523–528, 1981

    Article  PubMed  CAS  Google Scholar 

  • Kahan A, Amor B, Mankes CJ. A randomized double-blind trial of diltiazem in the treatment of Raynaud’s phenomenon. Circulation 68(Suppl. III): III–263, 1983

    Google Scholar 

  • Kahan A, Weber S, Amor B, Saprota L, Hodara M. Nifedipine and Raynaud’s phenomenon. Annals of Internal Medicine 94: 546, 1981

    PubMed  CAS  Google Scholar 

  • Kahan A, Weber S, Amor B, Saporta L, Hodara M, et al. Etude controlee de la nifedipine dans le traitement du phenomene de Raynaud. Revue de Rheumatisme 49: 337–343, 1982

    CAS  Google Scholar 

  • Kinney EL, Nicholas GG, Gallo J, Pontoriero C, Zelis R. The treatment of severe Raynaud’s phenomenon with verapamil. Journal of Clinical Pharmacology 22: 74–76, 1982

    PubMed  CAS  Google Scholar 

  • Louis P. A double blind placebo controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 21: 235–239, 1981

    Article  PubMed  CAS  Google Scholar 

  • Louis P, Spierings EL. Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Cephalalgia 2: 197–203, 1982

    Article  PubMed  CAS  Google Scholar 

  • Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 34: 973–976, 1984

    Article  PubMed  CAS  Google Scholar 

  • Mentenopoulos G, Manafi Th, Logotheris J, Bostantzopoulou S. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 5(Suppl. 2): 135–140, 1985

    PubMed  Google Scholar 

  • Meyer JS, Nance M, Walker M, Zetusky WJ, Dowell RE. Migraine and cluster headache treatment with calcium antagonists supports a vascular pathogenesis. Headache 25: 358–367, 1985

    Article  PubMed  CAS  Google Scholar 

  • Olesen S, Lauritzen M, Tfelt-Hansen P. Spreading cerebral oligemia in classical and normal cerebral blood flow in common migraine. Headache 22: 242–248, 1982

    Article  PubMed  CAS  Google Scholar 

  • Ribeiro LG, Brandon TA, Horak JK, Ware JA, Miller RR, et al. Inhibition of platelet aggregation by verapamil: quantification by in vivo and in vitro techniques. Journal of Cardiovascular Pharmacology 4: 170–173, 1982

    Article  PubMed  CAS  Google Scholar 

  • Robinson BF, Dobbs RJ, Kelsey CR. Effects of nifedipine on resistance vessels, arteries and veins in man. British Journal of Clinical Pharmacology 10: 433–438, 1980

    Article  PubMed  CAS  Google Scholar 

  • Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon. New England Journal of Medicine 308: 880–883, 1983

    Article  PubMed  CAS  Google Scholar 

  • Sakai F, Meyer JS. Abnormal cerebrovascular reactivity in patients with migraine and cluster headache. Headache 19: 257–266, 1979

    Article  PubMed  CAS  Google Scholar 

  • Schwartz AC. Neurological recovery after cardiac arrest: clinical feasibility trial of calcium blockers. American Journal of Emergency Medicine 3: 1–10, 1985

    PubMed  CAS  Google Scholar 

  • Seaman J, Lovy M, MacCarter D, Steigerwald J. Verapamil in the treatment of secondary Raynaud’s phenomenon. Clinical Research 31: 77A, 1983

    Google Scholar 

  • Shapiro HM. Post-cardiac arrest therapy: calcium entry blockade and brain resuscitation. Anesthesiology 62: 384–387, 1985

    Article  PubMed  CAS  Google Scholar 

  • Skinhoj E. Hemodynamic studies within the brain during migraine. Archives of Neurology 29: 95–98, 1973

    Article  PubMed  CAS  Google Scholar 

  • Smith CD, McKendry RJR. Controlled trial of nifedipine in the treatment of Raynaud’s phenomenon. Lancet 2: 1299–1301, 1982

    Article  PubMed  CAS  Google Scholar 

  • Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. Journal of the American Medical Association 250: 2500–2502, 1983

    Article  PubMed  CAS  Google Scholar 

  • Somani P, Mayhew HE. Clinical indications for calcium channel blockers. Primary Care 12: 143–164, 1985

    PubMed  CAS  Google Scholar 

  • Sorge F, Marano E. Flunarizine v. placebo in childhood migraine. Cephalalgia 5(Suppl. 2): 145–148, 1985

    PubMed  Google Scholar 

  • Steardo L, Marano E, Barone P, Denman DW, Monteleone P, et al. Prophylaxis of migraine attacks with a calcium-channel blocker: flunarizine versus methysergide. Journal of Clinical Pharmacology 26: 524–528, 1986

    PubMed  CAS  Google Scholar 

  • Stone PH, Antman EM, Muller JE, Braunwald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Annals of Internal Medicine 93: 886–904, 1980

    PubMed  CAS  Google Scholar 

  • Vayssairat M, Capron L, Fiessinger JN, Mathieu JF, Housset E. Calcium-channel blockers and Raynaud’s disease. Annals of Internal Medicine 95: 243, 1981

    PubMed  CAS  Google Scholar 

  • Wilkins RH. Attempted prevention or treatment of intracranial arterial spasm: a survey. Neurosurgery 6: 198–210, 1980

    Article  PubMed  CAS  Google Scholar 

  • White CJ, Phillips WA, Abraham LA, Watson TD, Singleton PT. Objective benefit of nifedipine in the treatment of Raynaud’s phenomenon. American Journal of Medicine 80: 623–625, 1986

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Philadelphia College of Pharmacy and Science, Philadelphia, USA

    Karen J. Tietze, Marc L. Schwartz &  Peter H. Vlasses

  2. Divisions of Cardiology and Clinical Pharmacology, Jefferson Medical College, Philadelphia, USA

    Karen J. Tietze, Marc L. Schwartz &  Peter H. Vlasses

Authors
  1. Karen J. Tietze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc L. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter H. Vlasses
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tietze, K.J., Schwartz, M.L. & Vlasses, P.H. Calcium Antagonists in Cerebral/Peripheral Vascular Disorders. Drugs 33, 531–538 (1987). https://doi.org/10.2165/00003495-198733060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198733060-00001

Keywords

Search

Navigation